Drugs / Testosterone Cypionate
Testosterone Cypionate
also known as
Depo-Testosterone Injection · Andro-cyp · Azmiro · DEPO-Testosterone · Depotest · NSC-9157 · Testosterone 17.beta.-cyclopentanepropionate · Testosterone cipionate · +3 more
Small molecule targets AR via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TESTOSTERONE CYPIONATE | — | 1978-06-23 | fda.gov ↗ |
Trials 29 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02995330 Background | Feb 2017 → Jun 2021 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06111209 Comparator | Feb 2025 → Dec 2026 expected | female stress incontinence | Brigham and Women's Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03716739 Comparator | Mar 2019 → May 2025 | prostate cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00853502 Comparator | Dec 2008 → Oct 2016 | metabolic bone disorder | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07092527 Comparator | Dec 2025 → Nov 2028 expected | reproductive system disorder | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 4 | NCT06450405 Comparator | Feb 2025 | reproductive system disorder | University of California, San Diego | Terminated | No outcome recorded |
| Phase 4 | NCT04439799 Comparator | Aug 2020 → Feb 2023 | hypogonadism, male | University of Miami | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Testosterone Cypionate | “Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)- cyclopentylpropionate ester of the androgenic...” NCT04321551 ↗34“All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.” NCT04704505 ↗ |
| Known as | Andro-cyp | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | Azmiro | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | DEPO-Testosterone | “DEPO-Testosterone” NCT06100705 ↗ |
| Known as | Depo-Testosterone Injection | “DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic...” NCT01378299 ↗1“Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone.” NCT04363164 ↗ |
| Known as | Depotest | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | NSC-9157 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | Testosterone 17.beta.-cyclopentanepropionate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | Testosterone cipionate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | Testosterone cyclopentylpropionate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04757532 ↗ |
| Known as | Testosterone cypionate ciii | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Known as | Testosterone cypionate component of depo-testadiol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201101 ↗ |
| Action | Activate | “Androgen Receptor agonist” CHEMBL1201101 ↗ |
| Modality | Small molecule | — CHEMBL1201101 ↗ |
| Route | Intramuscular | “dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months” NCT00853502 ↗ |
| Target | AR | “Androgen Receptor agonist” CHEMBL1201101 ↗ |